PTSD, Trauma & Complex Emotional Patterns
Scientifically Grounded Relief for Treatment-Resistant Trauma
Understanding PTSD and Trauma
For individuals who have tried conventional treatment without lasting relief, IV ketamine therapy — combined with therapeutic support — offers a scientifically grounded, rapidly acting path toward healing from trauma.
Post-traumatic stress disorder (PTSD) is a chronic, debilitating condition that develops after exposure to threatening or shocking events. It affects an estimated 3.9% of the general population across the lifespan, with rates rising significantly among trauma-exposed individuals, veterans, first responders, and survivors of interpersonal violence. Women are disproportionately affected.
Symptoms extend well beyond flashbacks and nightmares. They typically include emotional numbing, persistent avoidance, hypervigilance, disrupted sleep, difficulty connecting with others, and a pervasive sense that the world is no longer safe. For many patients, these symptoms remain severe even after completing recommended first-line treatments — including SSRIs and trauma-focused psychotherapy.
“PTSD is a devastating condition, for which there are few pharmacological agents, often with a delayed onset of action and poor efficacy.”
— Ragnhildstveit et al., Therapeutic Advances in Psychopharmacology, 2023
Complex PTSD — often arising from prolonged, repeated trauma such as childhood abuse, domestic violence, or captivity — presents additional challenges: difficulty regulating emotion, distorted self-perception, and disrupted relationships. Standard treatments frequently fall short for this population.
Why Ketamine Shows Promise for PTSD
The biological underpinnings of PTSD involve significant disruption to glutamatergic neurotransmission — the brain’s primary excitatory signaling system — in regions including the prefrontal cortex, amygdala, hippocampus, and basal ganglia. These are the same neural circuits that govern fear memory, threat appraisal, and emotional regulation.
Ketamine, as an NMDA receptor antagonist, directly targets this glutamate system. Research suggests it works by rapidly restoring synaptic connectivity in trauma-affected circuits, potentially interfering with the reconsolidation of fear memories and supporting the brain’s capacity to extinguish conditioned fear responses.
Rapid
Symptom reduction often observed within hours to days — vs. weeks for conventional agents
~3.9%
Lifetime PTSD prevalence in general population; significantly higher among trauma-exposed groups
Low
Risk of manic switch or worsening dissociation confirmed in controlled clinical studies
A 2024 systematic review and meta-analysis published in Clinical Neuropsychiatry found that ketamine demonstrates promising efficacy in PTSD — particularly when paired with psychotherapy. Researchers noted that ketamine’s action on synaptic pathways in the hippocampus and prefrontal cortex may help reduce traumatic memory intensity and associated fear responses.
A landmark randomized controlled trial at the Icahn School of Medicine at Mount Sinai (Feder et al., published in American Journal of Psychiatry) demonstrated significant PTSD symptom reduction following repeated IV ketamine infusions in patients with chronic PTSD. Crucially, no worsening of dissociation, anxiety, or psychotic symptoms was observed — addressing an early concern about administering a dissociative agent to trauma survivors.
Ketamine-Assisted Therapy at BHWWC
Our approach to PTSD care reflects the emerging evidence that ketamine is most effective when integrated with psychological support. We collaborate directly with your existing therapist or can coordinate care with trauma-trained clinicians, following a model supported by multiple ongoing clinical trials combining ketamine with prolonged exposure, cognitive processing therapy, and written exposure therapy.
How the therapeutic window works
Research suggests that in the hours and days following a ketamine infusion, the brain enters a state of heightened neuroplasticity — a period during which emotional memories may be more accessible for therapeutic processing and new learning is more readily encoded. This is the window we help patients use.
What we treat in this category
• Chronic PTSD, including treatment-resistant presentations
• Complex PTSD arising from prolonged or repeated trauma
• Trauma with co-occurring depression or suicidal ideation
• Childhood trauma, adverse childhood experiences (ACEs)
• Trauma from military service, assault, accidents, or medical events
• Emotional dysregulation patterns linked to traumatic experience